Table 3.
Baseline Demographics Comparing Patients Included in the Analysis With Those Excluded Due to Missing Outcome Values
| All Patients (n =1808) | Excluded (n =878) | Included (n =930) | P Value, Comparing Excluded/Included | |
|---|---|---|---|---|
| Age, y | 62.5±12.2 | 62.7±12.7 | 62.3±11.7 | 0.5361 |
| Race, % black | 327 (18.4) | 192 (22.9) | 129 (14.2) | <0.0001 |
| Gender, % male | 1438 (79.5) | 698 (79.5) | 740 (79.6) | 1.0000 |
| Tobacco use, % | 883 (52.2) | 368 (48.2) | 515 (55.6) | 0.0029 |
| NYHA III to IV, % | 485 (29.2) | 211 (28.2) | 274 (29.9 | 0.3351 |
| Ischemic cardiomyopathy, % | 1271 (70.4) | 610 (69.6) | 661 (71.1) | 0.5362 |
| LVEF, %±SD | 20.8±6.1 | 21.1±6.1 | 20.5±6.0 | 0.0331 |
| Diabetes, % | 601 (35.6) | 283 (37.1) | 318 (34.3) | 0.2613 |
| Primary prevention, % | 1244 (75.6) | 574 (76.8) | 670 (74.6) | 0.3215 |
| β-Blocker, % | 1529 (85.4) | 738 (85.3) | 791 (85.4) | 1.0000 |
| ACEI/ARB, % | 1350 (79.6) | 604 (78.7) | 746 (80.3) | 0.4658 |
| Hypertension | 1080 (63.8) | 505 (66.0) | 575 (62.0) | 0.0938 |
| Dual chamber device, % | 511 (28.4) | 260 (29.7) | 251 (27.2) | 0.2642 |
| Biventricular device, % | 801 (44.5) | 372 (42.5) | 429 (46.5) | 0.2241 |
| De novo implant, % | 1049 (58.0) | 500 (56.9) | 549 (59.0) | 0.3953 |
NYHA indicates New York Heart Association; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.